New drug duo takes on hard-to-treat head and neck cancer
NCT ID NCT07040072
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests two drugs (finotonlimab and stapokibart) together in 10 adults with head and neck cancer that has come back or spread. All participants have already tried standard treatments. The main goals are to see if the combination is safe and whether it shrinks tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HNSCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Tongren Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Two punch of radiation and immunotherapy shrink head and neck tumors before surgery?
- Can a glowing drug light up head and neck tumors?
- Can a Two-Target antibody shrink Hard-to-Treat cancers?
- New drug combo aims to shrink oral cancers before surgery
- Modified herpes virus joins forces with immunotherapy to attack head and neck tumors
- New drug SKB571 takes on recurrent head and neck cancer